Fig. 6

The YAP1-SLC2A1 axis activates the Wnt/β-catenin signaling pathway and augments CRC progression by reducing GSK3β activity.A WB analyses of GSK3β, CTNNB1, and phos-CTNNB1 protein levels in SW480 and Caco-2 cells; B Activation of the Wnt/β-catenin signaling pathway in SW480 and Caco-2 cells determined using TOP/FOP luciferase reporter assays. SW480 and Caco-2 cells with stable SLC2A1 knockdown were treated with the Wnt agonist SKL2001. C Activation of the Wnt/β-catenin signaling pathway in SW480 and Caco-2 cells after SKL2001 treatment determined using TOP/FOP luciferase reporter assays; D CCK-8 assay to assess changes in cell viability; E EdU staining to evaluate the proliferative capacity. Cell experiments were repeated 3–5 times, with statistical analysis performed using Two-Way ANOVA, **P < 0.01